Remedy Robotics raises A$92m Series B, no sales team yet
San Francisco medtech Remedy Robotics closed US$62 million (A$92 million) Series B led by DCVC. Total disclosed funding now sits at US$97 million across seed, Series A and this round.
Backers include Blackbird, Tony Fadell's Build Collective, Divergent Capital, KdT Ventures, University of California's investment office, Skip Capital and Australian super fund Hostplus.
Cofounder David Bell is Perth-born, trained in cardiac surgery and air retrieval before Stanford. His company built the N1 robotic system: a specialist at a console steers a catheter through a patient's blood vessels remotely. Machine learning maps vessels to live X-ray. The pitch is stroke specialists in major cities treating patients hundreds of kilometres away in regional hospitals.
What this means for commercial teams: Nothing yet. The N1 has not received approval for routine clinical use anywhere. No revenue figures, no sales headcount, no CRO. This capital funds clinical trials across the University of California network, prototype placements and FDA approval work.
Remedy plans to place a prototype with the Australian Stroke Alliance, connecting metro specialists to regional patients. That is a trial partnership, not a commercial sale.
ANZ context: Nicolab is expanding its Melbourne headquarters with AI stroke imaging software. Wellumio in New Zealand raised NZ$9.75 million for portable brain imaging. Those are adjacent plays focused on diagnosis and imaging, not remote intervention. Different problem, different buyer.
The reality check: Remedy is R&D-stage medtech, not enterprise SaaS. No quota-carrying reps. No pipeline dashboards. The "sales" motion right now is clinical partnerships and trial-site recruitment, not hospital procurement.
If they clear FDA approval and move to commercialisation, that changes. Medical device sales is a different animal: long cycles, clinical evidence requirements, procurement committees. Watch for a VP of Commercial or Market Access hire as the signal they are moving from trials to revenue.
Until then, this is a research story with Australian investor involvement, not a sales hiring story.